These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 27684984)

  • 1. Application of the Bethesda Classification for Thyroid Fine-Needle Aspiration: Institutional Experience and Meta-analysis.
    Krauss EA; Mahon M; Fede JM; Zhang L
    Arch Pathol Lab Med; 2016 Oct; 140(10):1121-31. PubMed ID: 27684984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Presence of Hürthle Cells Does Not Increase the Risk of Malignancy in Most Bethesda Categories in Thyroid Fine-Needle Aspirates.
    Ren Y; Kyriazidis N; Faquin WC; Soylu S; Kamani D; Saade R; Torchia N; Lubitz C; Davies L; Stathatos N; Stephen AE; Randolph GW
    Thyroid; 2020 Mar; 30(3):425-431. PubMed ID: 32013786
    [No Abstract]   [Full Text] [Related]  

  • 3. Reclassifying formerly indeterminate thyroid FNAs using the Bethesda system reduces the number of inconclusive cases.
    Song JY; Chu YC; Kim L; Park IS; Han JY; Kim JM
    Acta Cytol; 2012; 56(2):122-9. PubMed ID: 22378073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System.
    Sullivan PS; Hirschowitz SL; Fung PC; Apple SK
    Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reproducibility of atypia of undetermined significance/follicular lesion of undetermined significance category using the bethesda system for reporting thyroid cytology when reviewing slides from different institutions: A study of interobserver variability among cytopathologists.
    Padmanabhan V; Marshall CB; Akdas Barkan G; Ghofrani M; Laser A; Tolgay Ocal I; David Sturgis C; Souers R; Kurtycz DF
    Diagn Cytopathol; 2017 May; 45(5):399-405. PubMed ID: 28217980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Yield of repeat fine-needle aspiration biopsy and rate of malignancy in patients with atypia or follicular lesion of undetermined significance: the impact of the Bethesda System for Reporting Thyroid Cytopathology.
    Chen JC; Pace SC; Chen BA; Khiyami A; McHenry CR
    Surgery; 2012 Dec; 152(6):1037-44. PubMed ID: 23040711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of malignancy according to sub-classification of the atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) category in the Bethesda system for reporting thyroid cytopathology.
    Kim SJ; Roh J; Baek JH; Hong SJ; Shong YK; Kim WB; Song DE
    Cytopathology; 2017 Feb; 28(1):65-73. PubMed ID: 27245883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [On-site fine-needle aspiration cytology of thyroid nodules. Quality assurance of the Bethesda System for Reporting Thyroid Cytopathology (2008)].
    Bak M; Péter I; Nyári T; Simon P; Újlaky M; Boér A; Kásler M
    Orv Hetil; 2015 Oct; 156(41):1661-6. PubMed ID: 26551169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Malignancy and Risk of Neoplasia in the Bethesda Indeterminate Categories: Study on 4,532 Thyroid Fine-Needle Aspirations from a Single Institution in India.
    Mahajan S; Srinivasan R; Rajwanshi A; Radotra B; Panda N; Dey P; Gupta N; Nijhawan R
    Acta Cytol; 2017; 61(2):103-110. PubMed ID: 28407624
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: evaluation of the Bethesda System for Reporting Thyroid Cytopathology.
    Broome JT; Solorzano CC
    Surgery; 2011 Dec; 150(6):1234-41. PubMed ID: 22136846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Follicular lesion of undetermined significance in thyroid FNA revisited.
    Walts AE; Mirocha J; Bose S
    Diagn Cytopathol; 2014 Jan; 42(1):18-22. PubMed ID: 23894017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the bethesda system for reporting thyroid cytopathology and similar precursor thyroid cytopathology reporting schemes.
    Wong LQ; Baloch ZW
    Adv Anat Pathol; 2012 Sep; 19(5):313-9. PubMed ID: 22885380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
    Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
    Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
    Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
    Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine needle aspiration of thyroid nodules in the pediatric population: a 12-year cyto-histological correlation experience at North Shore-Long Island Jewish Health System.
    Lale SA; Morgenstern NN; Chiara S; Wasserman P
    Diagn Cytopathol; 2015 Aug; 43(8):598-604. PubMed ID: 25728981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 'Indeterminate for malignancy' (Tir3/Thy3 in the Italian and British systems for classification) thyroid fine needle aspiration (FNA) cytology reporting: morphological criteria and clinical impact.
    Pagni F; Prada M; Goffredo P; Isimbaldi G; Crippa S; Di Bella C; Leone BE;
    Cytopathology; 2014 Jun; 25(3):170-6. PubMed ID: 23937572
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytology-Ultrasonography Risk-Stratification Scoring System Based on Fine-Needle Aspiration Cytology and the Korean-Thyroid Imaging Reporting and Data System.
    Hong MJ; Na DG; Baek JH; Sung JY; Kim JH
    Thyroid; 2017 Jul; 27(7):953-959. PubMed ID: 28463597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Bethesda system for reporting thyroid cytopathology: a single-center experience over 5 years.
    Kiernan CM; Broome JT; Solórzano CC
    Ann Surg Oncol; 2014 Oct; 21(11):3522-7. PubMed ID: 24796967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of malignancy rate in thyroid nodules according to the Bethesda system of fine-needle aspiration. Report from a tertiary center in the Southwestern region of Saudi Arabia.
    Al-Shraim MM; Kaood OM; Hussein MR; Al-Ahmary AM; Al Shehri GY; Jastania RA; Mahfouz AA; Abu-Eshy SA
    Saudi Med J; 2012 Feb; 33(2):167-71. PubMed ID: 22327757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining molecular testing and the Bethesda category III:VI ratio for thyroid fine-needle aspirates: A quality-assurance metric for evaluating diagnostic performance in a cytopathology laboratory.
    Gokozan HN; Dilcher TL; Alperstein SA; Qiu Y; Mostyka M; Scognamiglio T; Solomon JP; Song W; Rennert H; Beg S; Stern E; Goyal A; Siddiqui MT; Heymann JJ
    Cancer Cytopathol; 2022 Apr; 130(4):259-274. PubMed ID: 34962713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.